Dr. Reddy's Laboratories Limited American Depositary Shares
RDY
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Last trade$14.82
Day change+$0.115 (+0.78%)
Day range$14.54 – $14.93
Volume948,802
Market cap$12.25B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for RDY.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for RDY.
Recent news
Company coverage with links to the original publishers.
Dr. Reddy's Laboratories reported Q2 fiscal 2027 earnings of 12 cents per ADS, missing the 16-cent estimate, with revenues of $905M falling short of the $981M forecast. North American generics sales declined 23% due to lower lenalidomide sales, though the base business grew double-digits. Emerging Markets and India revenues rose 24% and 17% respectively, driven by new product launches and favorable currency movements. The company maintains a Zacks Rank #2 (Buy) rating.
Dr. Reddy's Laboratories reported double-digit underlying base business growth in Q2 2027, with Semaglutide supply chain issues resolved and reloading to begin by November 2026. Despite a 1.5% revenue decline due to reduced Lenalidomide sales, strong emerging market demand and a 52.1% gross margin provided stability. The company is advancing its biosimilar pipeline with Abatacept targeting FDA approval in December 2026 and scaling its CDMO segment to $100 million in trailing 12-month revenue.
Zacks analysts published research on 16 major stocks on October 12, 2026. Oracle faces headwinds from negative free cash flow and intense cloud competition but benefits from AI demand. American Express shows strong spending and customer acquisition despite rising expenses. Progressive maintains a neutral stance due to normalizing auto pricing and valuation concerns. Additional coverage includes Western Midstream, BrightSpring Health, and Dr. Reddy's Laboratories.
The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.
Pomerantz LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's announcement of weak Q1 FY2027 earnings with only $0.06 EPS, attributed to a ₹2.4 billion provision for out-of-specification semaglutide batches. The disclosure triggered a 9.4% stock price decline on July 22, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 24, 2026
$0.0834
Aug 5, 2026
recurring
Jul 25, 2025
$0.0915
Aug 6, 2025
recurring
Jul 30, 2024
$0.0952
Aug 12, 2024
recurring
Jul 28, 2023
$0.0965
Aug 11, 2023
recurring
Aug 1, 2022
$0.0757
Aug 12, 2022
recurring
Stock splits
Historical share-structure events and their execution dates.